A longtime leader in Asia, O’Melveny helps clients navigate commercial matters critical to their businesses.
Our local team represents clients from around the world in a broad range of matters, including cross-border disputes, joint ventures, complex mergers and acquisitions, financings, investment and capital market transactions, investment fund formation, international trade and regulatory matters, and restructurings and insolvencies. The firm’s experience in Asian countries has produced a wealth of government, business and legal relationships that generate valuable insights for our clients.
We have a multiple award-winning China practice, with offices in Beijing, Shanghai, and Hong Kong. We also maintain a thriving practice in Tokyo, where we opened an office in 1987, and a strong presence in Southeast Asia with an office in Singapore. Following the opening of the Korean legal market, we established a “foreign legal consultant office” in Seoul, a natural outgrowth of our long history of representing Korean clients. Today, we’re among the most active international law firms in Korea.
We are immersed in the culture and practices of Asia. Many of our lawyers are native speakers of Asian languages, including Korean, Mandarin, Cantonese, and Japanese. Our lawyers also have strong knowledge of local laws and collectively have legal practicing qualifications spanning China, Hong Kong, Japan, Korea, and Singapore. In addition, many have practicing qualifications and experience in the United States, England, and other Western jurisdictions, including a strong team of UK-trained solicitors and barristers.
Advanced Micro Devices, Inc.O’Melveny represented Advanced Micro Devices (AMD) in a global fight against Intel Corporation for monopolizing the x86-microprocessor industry through scare tactics and coercion. With litigation and investigations spanning the US, EU, and Asia, O’Melveny helped AMD secure important victories. Read
BGI-ShenzhenA multi-office, multi-practice O’Melveny team represented BGI Shenzhen, a China based genomic research and sequencing company, in its US$117.6 million acquisition of Complete Genomics and its successful defense of the transaction against a hostile competing bid. Read
Case Study: Akeso BiopharmaO’Melveny advised Akeso Biopharma, a leading Chinese clinical-state biopharmaceutical company specializing in oncology and immunology therapies, in its listing and IPO on the Hong Kong Stock Exchange. Read
Case Study: CJ ENMO’Melveny advised CJ ENM, the leading entertainment company originated from Korea, in a definitive agreement to acquire an 80% stake of the scripted business of US-based global premium content studio, Endeavor Content, from its parent company Endeavor Group Holdings for an enterprise valuation of US$850 million. Read
Chinese Company Public OfferingsO'Melveny has advised on multiple Chinese company public offerings, including representing eHi, China’s largest car services provider and second largest rental car provider, in its US$120 million initial public offering and US$50 million concurrent private placements. Read
Giant InteractiveO’Melveny successfully defended Giant Interactive, one of China’s leading online game developers and operators, in a shareholder class action seeking to enjoin Giant’s proposed going-private transaction, which O’Melveny also successfully handled. Read
GICO’Melveny represented GIC, Singapore’s sovereign wealth fund, in its investment in the US$1.26 billion equity financing of NYSE-listed XPO Logistics, one of the largest providers of freight brokerage, freight forwarding, and expedited freight transportation. Read
HoneywellWhen Honeywell’s US$5.1 billion acquisition of the Elster Division of Melrose Industries plc drew scrutiny from antitrust authorities around the world, O’Melveny lawyers worldwide mobilized to defend the transaction before the Federal Trade Commission, China’s Ministry of Commerce, and the European Commission. Read
IBM Corp.We represented IBM Corporation in securing CFIUS clearances to sell its x86 server business to Lenovo Group Ltd. Read
Lionsgate Entertainment Corp.O’Melveny represented Lionsgate in its multiyear slate co-financing deal with Hunan TV & Broadcast Intermediary Co. Ltd. in reportedly the biggest investment in Hollywood by a Chinese company to date. Read
Meinian Onehealth Healthcare GroupO’Melveny is advising a consortium led by Meinian Onehealth on its proposed take-private of competitor iKang Healthcare Group. Read
Mongolian Mining and Gas CompaniesO’Melveny obtained a significant victory for two Mongolian mining and gas companies in an arbitration arising from a series of sales contracts entered into with a leading Japanese trading company for the purchase of mining equipment. Read
NextVR, Inc.NextVR, an innovative technology company, turned to O’Melveny to help raise US$80 million in a Series B funding round to broadcast live events in virtual reality. Read
Products Manufacturing CompanyO’Melveny helped a US specialty engineered products manufacturing company on the establishments of various joint venture projects in China, including an equity joint venture with a soft axle and soft tube factory in Ningbo, an equity joint venture with an auto cable factory in Shengyang, and an equity joint venture producing auto parts in Shanghai. Read
Sailing Capital Management Co., Ltd.O'Melveny advised China-based Sailing Capital Management on its investment in MobilEye, an Israeli company focused on advanced image sensing and processing technology for automotive applications. Read
SamsungO’Melveny has defended Samsung in numerous patent infringement and antitrust matters over the years, including two consolidated patent infringement lawsuits involving dozens of Samsung’s flagship products and a multibillion-dollar price-fixing claim. Read
We prevailed for Samsung Electro-Mechanics, Co. Ltd. in an important patent infringement trial before the International Trade Commission.Read
SK hynix Inc.O’Melveny helped SK hynix Inc. (formerly Hynix Semiconductor) obtain a favorable settlement in long-running patent and antitrust litigation with Rambus, Inc. The 13-year dispute involved litigation on two continents, in multiple trial courts, multiple appellate proceedings and litigation before multiple agencies. Read
Warner Bros.O’Melveny represented Warner Bros. in a joint venture with a consortium led by private equity firm China Media Capital (CMC) to launch a movie studio division, Flagship Entertainment Group. Read
WuXi PharmaTechO’Melveny represented NYSE-listed WuXi PharmaTech (Cayman) Inc., a leading technology company serving the pharmaceutical, biotechnology, and medical device industries in the US and China, in its merger with a group of private equity investors and the company’s founders in a going-private transaction valued at US$3.3 billion. Read
- 1Verge Holdings Ltd.
- Asiana Airlines
- Bank of Qingdao
- BGI Shenzhen
- Celltrion Healthcare
- China Broadband Capital
- CJ E&M
- Giant Interactive Group Inc.
- Hengxing Gold
- Huayi Brothers
- Hyundai Heavy Industries
- Hyundai Mobis
- Hyundai Motor Company
- KIA Motors
- Kumho Petrochemical
- Mitsui & Co.
- Phoenix Education
- Phoenix Healthcare Group
- POSCO Energy
- Samsung Electronics
- Shanghai Haohai Biological Technology
- SK Hynix
- Skyworks Solutions, Inc.
- Western Digital Corporation
Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.